Biocept Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Biocept ha aumentado sus beneficios a una tasa media anual de 4.1%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento anual de 12.7%. Los ingresos han ido creciendo a una tasa media de 34.9% al año.

Información clave

4.1%

Tasa de crecimiento de los beneficios

91.7%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	34.9%
Rentabilidad financiera	-10,554.1%
Margen neto	-2,255.5%
Última actualización de beneficios	30 Jun 2023

Actualizaciones de resultados anteriores recientes

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23

Recent updates

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Apr 17

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Nov 23

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Aug 19

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Jul 03

Biocept and CLEARED4 ink collaboration agreement

Jun 09

Biocept enters COVID-19 testing partnership

Apr 28

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Mar 13

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Biocept. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqCM:BIOC Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Jun 23	1	-31	15	4
31 Mar 23	7	-37	17	5
31 Dec 22	26	-32	23	6
30 Sep 22	41	-25	25	6
30 Jun 22	57	-16	27	6
31 Mar 22	63	-8	26	6
31 Dec 21	61	-3	21	5
30 Sep 21	66	2	21	5
30 Jun 21	55	-2	20	4
31 Mar 21	44	-7	18	5
31 Dec 20	27	-18	16	5
30 Sep 20	11	-25	14	5
30 Jun 20	6	-26	13	5
31 Mar 20	6	-28	13	5
31 Dec 19	6	-25	13	5
30 Sep 19	5	-26	13	5
30 Jun 19	4	-27	13	5
31 Mar 19	3	-25	12	5
31 Dec 18	3	-25	13	4
30 Sep 18	3	-25	13	4
30 Jun 18	4	-24	14	4
31 Mar 18	4	-24	14	4
31 Dec 17	5	-22	14	3
30 Sep 17	5	-20	13	3
30 Jun 17	5	-19	13	3
31 Mar 17	5	-18	12	3
31 Dec 16	3	-18	12	3
30 Sep 16	2	-19	11	3
30 Jun 16	1	-19	11	3
31 Mar 16	1	-18	10	3
31 Dec 15	1	-17	10	3
30 Sep 15	0	-16	9	3
30 Jun 15	0	-16	8	4
31 Mar 15	0	-15	7	4
31 Dec 14	0	-16	7	4
30 Sep 14	0	-14	6	4
30 Jun 14	0	-13	5	4
31 Mar 14	0	-12	4	3
31 Dec 13	0	-9	3	3
30 Sep 13	0	-10	2	4
30 Jun 13	0	-10	2	4
31 Mar 13	0	-11	3	5
31 Dec 12	0	-12	3	7

Ingresos de calidad: BIOC actualmente no es rentable.

Margen de beneficios creciente: BIOC actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: BIOC no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 4.1% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de BIOC en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: BIOC no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).

Rentabilidad financiera

Alta ROE: BIOC tiene una rentabilidad financiera negativa (-10554.14%), ya que actualmente no es rentable.

Biocept Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Second quarter 2023 earnings released: US$3.50 loss per share (vs US$16.83 loss in 2Q 2022)

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)

First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)

Recent updates

Biocept, Inc.(OTCPK:BIOC.Q) dropped from NASDAQ Composite Index

Biocept's Securities To Be Delisted from Nasdaq

Biocept, Inc.(NasdaqCM:BIOC) dropped from S&P TMI Index

Biocept, Inc. Announces the Full Enrollment of 40 Subjects with Breast or Non-Small Cell Lung Cancer

New minor risk - Revenue size

Second quarter 2023 earnings released: US$3.50 loss per share (vs US$16.83 loss in 2Q 2022)

Biocept, Inc. Announces Executive Changes

Biocept Expects to Receive Non-Compliance Notice Form Nasdaq

No longer forecast to breakeven

No longer forecast to breakeven

Biocept, Inc. (NASDAQ:BIOC) Shares Fly 48% But Investors Aren't Buying For Growth

Forecast to breakeven in 2025

Biocept, Inc. Appoints Quyen Dao-Haddock to the Board of Directors

Biocept, Inc. announced delayed 10-Q filing

Biocept Receives Non-Compliance Letter from Nasdaq

Biocept, Inc. Expands Commercial Offering of Cnside(Tm) Assay to Most Cancers That Metastasize to the Central Nervous System

Biocept Announces Receipt of Deficiency Notice from Nasdaq Regarding Requirement to Timely Quarterly Report on Form 10-Q

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc. announced delayed 10-Q filing

Biocept, Inc., Annual General Meeting, Jun 10, 2022

Biocept, Inc. announced delayed annual 10-K filing

Biocept, Inc. Appoints Philippe Marchand as Chief Operating Officer

Investor sentiment deteriorated over the past week

Third quarter 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Biocept, Inc. Announces Management Changes

Biocept Names Darrell Taylor as Senior Vice President, General Counsel and Chief Compliance Officer

Biocept’s CNSide Cerebrospinal Fluid Assay Identifies Actionable HER2 Mutations in Patients with Breast Cancer that has Metastasized to the Brain

Investor sentiment improved over the past week

Biocept Launches Combined COVID-19 and Influenza Test to Provide Answers During Peak Flu Season

Statutory Earnings May Not Be The Best Way To Understand Biocept's (NASDAQ:BIOC) True Position

Third quarter 2021 earnings released: EPS US$0.056 (vs US$0.43 loss in 3Q 2020)

Biocept, Inc. Implements Covid-19 Testing Program at Select California Community Colleges

Biocept to Present Data at RAS-Targeted Drug Development Summit Showing Ability of Its Switch-BlockerTM Technology to Detect Rare Cancer Mutations

Biocept’s CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

Just In: One Analyst Has Become A Lot More Bullish On Biocept, Inc.'s (NASDAQ:BIOC) Earnings

Second quarter 2021 earnings released: US$0.14 loss per share (vs US$0.51 loss in 2Q 2020)

Medicare Issues Local Coverage Determination for Biocept’s Target Selector™ Breast Cancer Assay to Detect the HER2 Biomarker from Circulating Tumor Cells

Shareholders Will Probably Hold Off On Increasing Biocept, Inc.'s (NASDAQ:BIOC) CEO Compensation For The Time Being

Biocept and CLEARED4 ink collaboration agreement

Consensus revenue estimates increase to US$37.5m

First quarter 2021 earnings released: EPS US$0.19 (vs US$1.06 loss in 1Q 2020)

Price target decreased to US$12.00

Biocept enters COVID-19 testing partnership

Full year 2020 earnings released: US$1.50 loss per share (vs US$12.23 loss in FY 2019)

Biocept (NASDAQ:BIOC) Shareholders Have Enjoyed An Impressive 104% Share Price Gain

Aegea Biotechnologies Announces Supply Agreement with Biocept for New COVID-19 Test with the Ability to Distinguish Virus Strains and Quantify Viral Load

Biocept and Protean BioDiagnostics Establish Research Collaboration to Demonstrate Advantages of Biocept’s Target Selector™ Assay Kit for Non-Small Cell Lung Cancer Patients

New 90-day high: US$6.70

We're Keeping An Eye On Biocept's (NASDAQ:BIOC) Cash Burn Rate

New 90-day high: US$6.23

Biocept, Inc. Enters into Laboratory Services Agreements with Independent Physician Associations

Biocept, Inc. (NASDAQ:BIOC): Is Breakeven Near?

Biocept, Inc. Announces to Receives More Than 150,000 Samples for Covid-19 RT-PCR Testing

Biocept, Inc.'s Target Selector™ Liquid Biopsy Demonstrate High Accuracy When Used for Monitoring the Progression of Metastatic Breast Cancer in Study Conducted at Johns Hopkins Sidney Kimmel Cancer Center

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations, earnings disappoint

Biocept's assays viable and sensitive for detecting tumor cells and biomarkers

Third quarter 2020 earnings released: US$0.43 loss per share

Revenue beats expectations, earnings disappoint

Analysts update estimates

Biocept +4% on COVID-19 testing update

Biocept, Inc. Receives Hong Kong Patent Covering the Enhanced Detection of Rare Cells, Including Cancer Cells

Biocept, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Biocept, Inc. Provides Update on COVID-19 Testing with More than 50,000 Specimens Received

Biocept, Inc. Announces That Highmark Has Made A Positive Coverage Determination on Target Selector Liquid Biopsy

Biocept, Inc. Provides COVID-19 Testing Update with More Than 21,000 COVID-19 Specimens Received and More Than 20,000 Specimens Processed

Analysts update estimates

Price target raised to US$2.03

Biocept, Inc. Announces One-For-Ten Reverse Stock Split to Regain Compliance

Desglose de ingresos y gastos
Beta